165 related articles for article (PubMed ID: 37974184)
1. Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study.
Muenzer J; Burton BK; Amartino HM; Harmatz PR; Gutiérrez-Solana LG; Ruiz-Garcia M; Wu Y; Merberg D; Alexanderian D; Jones SA
Orphanet J Rare Dis; 2023 Nov; 18(1):357. PubMed ID: 37974184
[TBL] [Abstract][Full Text] [Related]
2. Analysis of cognitive ability and adaptive behavior assessment tools used in an observational study of patients with mucopolysaccharidosis II.
Yee KS; Wu Y; Harrington M; Waisbren SE
Orphanet J Rare Dis; 2021 Dec; 16(1):501. PubMed ID: 34863240
[TBL] [Abstract][Full Text] [Related]
3. Cognitive and adaptive behaviors associated with disease severity and genotype in patients with mucopolysaccharidosis II.
Yee KS; Alexanderian D; Merberg D; Natarajan M; Wang S; Wu Y; Whiteman DAH
Mol Genet Metab; 2023 Nov; 140(3):107652. PubMed ID: 37506513
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.
Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
Mol Genet Metab; 2022; 137(1-2):127-139. PubMed ID: 36027721
[TBL] [Abstract][Full Text] [Related]
5. A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT.
Yee KS; Chirila C; Davenport E; Mladsi D; Barnett C; Kronenberger WG
Orphanet J Rare Dis; 2023 Nov; 18(1):343. PubMed ID: 37915038
[TBL] [Abstract][Full Text] [Related]
6. Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
Mol Genet Metab; 2022; 137(1-2):92-103. PubMed ID: 35961250
[TBL] [Abstract][Full Text] [Related]
7. An observational, prospective, multicenter, natural history study of patients with mucopolysaccharidosis type IIIA.
Wijburg FA; Aiach K; Chakrapani A; Eisengart JB; Giugliani R; Héron B; Muschol N; O'Neill C; Olivier S; Parker S
Mol Genet Metab; 2022 Feb; 135(2):133-142. PubMed ID: 34991944
[TBL] [Abstract][Full Text] [Related]
8. Quantifying medical manifestations in Hurler syndrome with the infant physical symptom score: associations with long-term physical and adaptive outcomes.
Ahmed A; Rudser K; King KE; Eisengart JB; Orchard PJ; Shapiro E; Whitley CB
Mol Genet Metab; 2022 May; 136(1):22-27. PubMed ID: 35304037
[TBL] [Abstract][Full Text] [Related]
9. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
[TBL] [Abstract][Full Text] [Related]
10. Ability change across multiple domains in mucopolysaccharidosis (Sanfilippo syndrome) type IIIA.
Shapiro EG; Eisengart JB; Whiteman D; Whitley CB
Mol Genet Metab; 2024 Feb; 141(2):108110. PubMed ID: 38151384
[TBL] [Abstract][Full Text] [Related]
11. Vineland adaptive behavior scales to identify neurodevelopmental problems in children with Congenital Hyperinsulinism (CHI).
Salomon-Estebanez M; Mohamed Z; Michaelidou M; Collins H; Rigby L; Skae M; Padidela R; Rust S; Dunne M; Cosgrove K; Banerjee I; Nicholson J
Orphanet J Rare Dis; 2017 May; 12(1):96. PubMed ID: 28532504
[TBL] [Abstract][Full Text] [Related]
12. Clinical investigator perspectives on patient outcomes in children with neuronopathic mucopolysaccharidosis II during intrathecal idursulfase-IT treatment.
Yee KS; Alexanderian D; Martin S; Olayinka-Amao B; Whiteman DAH
Orphanet J Rare Dis; 2024 Apr; 19(1):158. PubMed ID: 38610004
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal trajectories of intellectual and adaptive functioning in adolescents and adults with Williams syndrome.
Fisher MH; Lense MD; Dykens EM
J Intellect Disabil Res; 2016 Oct; 60(10):920-32. PubMed ID: 27273269
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Arrest Outcomes in Children With Preexisting Neurobehavioral Impairment.
Christensen JR; Slomine BS; Silverstein FS; Page K; Holubkov R; Dean JM; Moler FW;
Pediatr Crit Care Med; 2019 Jun; 20(6):510-517. PubMed ID: 30807545
[TBL] [Abstract][Full Text] [Related]
15. Interim results of adaptive functioning and neurodevelopment in BUTTERFLY - An observational study of children and adolescents with Dravet syndrome.
Sullivan J; Wirrell E; Knupp KG; Chen D; Zafar M; Flamini R; Stutely J; Brathwaite C; Ventola P; Avendaño J; Parkerson KA; Wyant N; Ticho B
Epilepsy Behav; 2022 Dec; 137(Pt A):108955. PubMed ID: 36332561
[TBL] [Abstract][Full Text] [Related]
16. Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II.
Muenzer J; Vijayaraghavan S; Stein M; Kearney S; Wu Y; Alexanderian D
Genet Med; 2022 Jul; 24(7):1437-1448. PubMed ID: 35588317
[TBL] [Abstract][Full Text] [Related]
17. Neurobehavioral Outcomes in Children After Out-of-Hospital Cardiac Arrest.
Slomine BS; Silverstein FS; Christensen JR; Holubkov R; Page K; Dean JM; Moler FW;
Pediatrics; 2016 Apr; 137(4):. PubMed ID: 26940987
[TBL] [Abstract][Full Text] [Related]
18. The natural history of neurocognition in MPS disorders: A review.
Shapiro EG; Eisengart JB
Mol Genet Metab; 2021 May; 133(1):8-34. PubMed ID: 33741271
[TBL] [Abstract][Full Text] [Related]
19. Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B.
Whitley CB; Cleary M; Eugen Mengel K; Harmatz P; Shapiro E; Nestrasil I; Haslett P; Whiteman D; Alexanderian D
J Pediatr; 2018 Jun; 197():198-206.e2. PubMed ID: 29661560
[TBL] [Abstract][Full Text] [Related]
20. Projected Retained Ability Score (PRAS): A New Methodology for Quantifying Absolute Change in Norm-Based Psychological Test Scores Over Time.
Kronenberger WG; Harrington M; Yee KS
Assessment; 2021 Mar; 28(2):367-379. PubMed ID: 31516019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
